Apellis Stock Financials

APLS
 Stock
  

USD 50.36  2.84  5.98%   

Apellis Pharmaceuticals Average Equity is relatively stable at the moment as compared to the past year. Apellis Pharmaceuticals reported last year Average Equity of 12.88 Million. As of 12/09/2022, Invested Capital Average is likely to grow to about 600.2 M, while Average Assets are likely to drop slightly above 603.9 M.
  
With this module, you can analyze Apellis financials for your investing period. You should be able to track the changes in Apellis Pharmaceuticals individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Apellis Most Recent Estimates

EPS Estimate Next Quarter
(1.58) 
Diluted Eps
(7.87) 
EPS Estimate Current Year
(6.32) 
EPS Estimate Next Year
(5.31) 
EPS Estimate Current Quarter
(1.45) 
Earnings Share
(7.87) 
Understanding current and past Apellis Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Apellis Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Apellis Pharmaceuticals' assets may result in an increase in income on the income statement.

Total Debt

203.09 Million

The financial analysis of Apellis Pharmaceuticals is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Apellis Pharmaceuticals includes many different criteria found on its balance sheet. For example, investors should never minimize Apellis Pharmaceuticals' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Apellis Pharmaceuticals' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Apellis Pharmaceuticals.

Apellis Pharmaceuticals Cash

Chance Of Financial Distress
Less than 23
Apellis Pharmaceuticals has less than 23 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Apellis Pharmaceuticals stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Apellis Pharmaceuticals' official financial statements usually reflect Apellis Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Apellis Pharmaceuticals. For example, before you start analyzing numbers published by Apellis accountants, it's critical to develop an understanding of what Apellis Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Apellis Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Apellis Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Apellis Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Apellis Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Apellis Pharmaceuticals' management to manipulate its earnings.

Apellis Pharmaceuticals Company Summary

Apellis Pharmaceuticals competes with Seagen, United Therapeutics, CSL, Exelixis, and Novo Nordisk. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 476 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0001492422
ISINUS03753U1060
RegionNorth America
Business Address100 Fifth Avenue,
SectorBiotechnology
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.apellis.com
Phone617 977 5700
CurrencyUSD - US Dollar
You should never invest in Apellis Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Apellis Stock, because this is throwing your money away. Analyzing the key information contained in Apellis Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Apellis Pharmaceuticals Key Financial Ratios

Generally speaking, Apellis Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Apellis Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Apellis Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Apellis Pharmaceuticals reports annually and quarterly.

Apellis Pharmaceuticals Key Balance Sheet Accounts

201720182019202020212022 (projected)
Accounts Payable3.66 M10.25 M8.36 M8.48 M16.91 M18.24 M
Total Assets182.13 M203.53 M389.24 M960.57 M881.76 M951.38 M
Current Assets182.02 M202.44 M373.09 M917.19 M824.05 M889.1 M
Assets Non Current116.15 K1.09 M16.15 M43.38 M57.72 M62.27 M
Cash and Equivalents175.64 M176.27 M351.99 M565.78 M640.19 M690.73 M
Shareholders Equity148.94 M160.97 M34.23 M204.56 M198.66 M214.35 M
Total Liabilities33.19 M42.56 M355.02 M756.01 M683.1 M737.03 M
Current Liabilities6.55 M17.02 M65.75 M128.33 M131.85 M142.26 M

Apellis Pharmaceuticals Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Apellis Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Consolidated Income(51.01 M)(127.5 M)(304.71 M)(344.87 M)(746.35 M)(765.99 M)
Earning Before Interest and Taxes EBIT(50.63 M)(124.99 M)(299.42 M)(313.09 M)(732.76 M)(752.04 M)
Earning Before Interest and Taxes USD(50.63 M)(124.99 M)(299.42 M)(313.09 M)(732.76 M)(752.04 M)
Net Income(51.01 M)(127.5 M)(304.71 M)(344.87 M)(746.35 M)(765.99 M)
Net Income Common Stock(51.01 M)(127.5 M)(304.71 M)(344.87 M)(746.35 M)(765.99 M)
Net Income Common Stock USD(51.01 M)(127.5 M)(304.71 M)(344.87 M)(746.35 M)(765.99 M)
Operating Expenses50.91 M127.92 M288.01 M464.37 M602.64 M650.22 M
Research and Development Expense40.3 M105.29 M220.97 M299.92 M345.87 M373.17 M
Selling General and Administrative Expense10.46 M22.64 M67.05 M139.4 M176.77 M190.73 M
Weighted Average Shares13.87 M54.4 M62.23 M75.16 M84.42 M91.09 M
Weighted Average Shares Diluted13.87 M54.4 M62.23 M75.16 M84.42 M91.09 M

Apellis Pharmaceuticals Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Apellis Pharmaceuticals. It measures of how well Apellis is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Apellis Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Apellis had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Apellis Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Net Cash Flow or Change in Cash and Cash Equivalents150.78 M624 K175.72 M215.06 M74.71 M91.27 M
Net Cash Flow from Financing197.38 M131.9 M388.54 M692.18 M392.24 M318.22 M
Net Cash Flow from Operations(46.6 M)(131.24 M)(211.14 M)(160.49 M)(563.13 M)(577.95 M)
Share Based Compensation5.42 M7.73 M21.14 M45.38 M70.67 M76.25 M

Apellis Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Apellis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Apellis Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Apellis Pharmaceuticals competition to find correlations between indicators driving Apellis Pharmaceuticals's intrinsic value. More Info.
Apellis Pharmaceuticals is rated below average in operating margin category among related companies. It is rated below average in price to earnings to growth category among related companies . Apellis Pharmaceuticals Operating Margin is relatively stable at the moment as compared to the past year. Apellis Pharmaceuticals reported last year Operating Margin of -76.74. Comparative valuation analysis is a catch-all model that can be used if you cannot value Apellis Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Apellis Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Apellis Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Apellis Pharmaceuticals Systematic Risk

Apellis Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Apellis Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was sixty with a total number of output elements of one. The Beta measures systematic risk based on how returns on Apellis Pharmaceuticals correlated with the market. If Beta is less than 0 Apellis Pharmaceuticals generally moves in the opposite direction as compared to the market. If Apellis Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Apellis Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Apellis Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Apellis Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
.

About Apellis Pharmaceuticals Financials

What exactly are Apellis Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Apellis Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential Apellis Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Apellis Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Apellis Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Apellis Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Apellis Pharmaceuticals is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Apellis has grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Apellis Pharmaceuticals December 9, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Apellis Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Apellis Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Apellis Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Apellis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Apellis Pharmaceuticals's daily price indicators and compare them against related drivers.
Information Ratio(0.08)
Maximum Drawdown22.7
Value At Risk(6.09)
Potential Upside4.42
Please continue to Trending Equities. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for analysis

When running Apellis Pharmaceuticals price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Is Apellis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.6 B
Quarterly Revenue Growth YOY
2.904
Return On Assets
(0.46) 
Return On Equity
(5.07) 
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Apellis Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.